xanderla 3,6 mg implants pilnšļircē
teva b.v., netherlands - goserelīns - implants pilnšļircē - 3,6 mg
xanderla 10,8 mg implants pilnšļircē
teva b.v., netherlands - goserelīns - implants pilnšļircē - 10,8 mg
zoladex 3,6 mg implants
astrazeneca uk limited, united kingdom - goserelīns - implants pilnšļircē - 3,6 mg
zoladex la 10,8 mg implants
astrazeneca uk limited, united kingdom - goserelīns - implants pilnšļircē - 10,8 mg
reseligo 3,6 mg implants pilnšļircē
zentiva, k.s., czech republic - goserelīns - implants pilnšļircē - 3,6 mg
reseligo 10,8 mg implants pilnšļircē
zentiva, k.s., czech republic - goserelīns - implants pilnšļircē - 10,8 mg
reseligo 10,8 mg implants pilnšļircē
alvogen ipco s.a.r.l, luxembourg - goserelīns - implants pilnšļircē - 10,8 mg
reseligo 10,8 mg implants pilnšļircē
alvogen ipco s.a.r.l, luxembourg - goserelīns - implants pilnšļircē - 10,8 mg
leptoprol 5 mg implants pilnšļircē
sandoz d.d., slovenia - leiprorelīns - implants pilnšļircē - 5 mg
firmagon
ferring pharmaceuticals a/s - degarelix - prostatas audzēji - endokrīnā terapija - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.